Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540450 | 1.00 | DRD2 (0.54) | DRD2SLC6A4HTR2AKCNH2HTR7 | |
| SCHEMBL2541849 | 0.91 | HTR2A (0.52) | HTR2AHTR7DRD3HTR1A | |
| SCHEMBL2541853 | 0.91 | HTR2A (0.52) | HTR2AHTR7DRD3HTR1A | |
| SCHEMBL17180607 | 0.85 | ACHE (0.56) | DRD2SLC6A4HTR2AKCNH2HTR7 | |
| SCHEMBL2537153 | 0.83 | HTR2A (0.52) | DRD2SLC6A4HTR2AKCNH2HTR7 | |
| SCHEMBL2537150 | 0.83 | HTR2A (0.52) | DRD2SLC6A4HTR2AKCNH2HTR7 | |
| SCHEMBL14844353 | 0.83 | DRD2 (0.45) | DRD2HTR2AKCNH2HTR7HTR1A | |
| SCHEMBL14853326 | 0.83 | DRD2 (0.45) | DRD2HTR2AKCNH2HTR7HTR1A | |
| SCHEMBL8351112 | 0.77 | HTR2A (0.62) | DRD2SLC6A4HTR2AKCNH2HTR7 | |
| SCHEMBL8350139 | 0.77 | DRD2 (0.63) | DRD2SLC6A4HTR2AKCNH2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571879-B1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-8481528-B2 | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1B, AVPR1A, AVPR2 | DRD2 262/4885SLC6A4 874/4885HTR2A 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.